Pharmexcil suspends Marion Biotech membership
The Hindu
The council initiated action after the company did not furnish the details it had sought after reports of the death of children allegedly after consuming Doc-1 Max, a cough syrup supplied by the company
Pharmaceuticals Export Promotion Council of India has suspended from its membership Marion Biotech, the Noida-based drugmaker under the scanner after the death of 18 children in Uzbekistan.
The suspension is with immediate effect, Pharmexcil Director General Ravi Udaya Bhaskar said on Friday. The council, a body under the Union Commerce Ministry, initiated action after the company did not furnish the details it had sought after reports of the death of children allegedly after consuming Doc-1 Max, a cough syrup supplied by the company.
The alleged supply of substandard medicines by the company, leading to the deaths, has brought bad reputation to the Indian pharma industry. The development is also likely to have an impact on the trust of international agencies on Indian pharma exports, Pharmexcil said. Besides seeking information on licensees to whom the company had supplied Doc-1 Max, importers’ details, manufacturing licence copies and product permissions, the Council had advised Marion to investigate reasons behind the alleged serious adverse events.
The company is registered with Pharmexcil as a small scale manufacturer since 2010 and as a merchant exporter from 2016. The action came on a day when Union Health Minister Mansukh Mandaviya said “all manufacturing activities of Marion Biotech at the Noida unit have been stopped yesterday night.” This followed an inspection by the Central Standard Drugs Control Organisation (CDSCO) in the wake of reports of contamination in the cough syrup, he tweeted.
In October, Pharmexcil had suspended from its membership Maiden Pharmaceuticals after the company’s syrups were linked to acute kidney injury resulting in the death of at least 63 children in The Gambia. Companies suspended from membership by Pharmexcil will not be entitled to incentives made available by the government under the Market Access initiative for exporters.
Viatris faces U.S. FDA import alert for products from Indore plant, exceptions made for certain shortages.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.
Adani Group acquires Air Works, India's largest MRO company, expanding its aviation services with a ₹400 crore deal.